Tanaka, Yasuhito
Nakamoto, Daisuke
Piao, Yi
Mizutani, Hajime
Wakabayashi, Ryozo
Saito, Yoshiyuki
Kwon, Kyung min
Dickinson, Harriet
Funding for this research was provided by:
Gilead Sciences K.K.
Article History
Received: 21 February 2024
Accepted: 14 May 2024
First Online: 29 May 2024
Declarations
:
: Yasuhito Tanaka received honoraria from Gilead Sciences Inc., AbbVie GK., Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Holdings Co., Ltd., OTSUKA Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, GlaxoSmithKline PLC., and GlaxoSmithKline PLC.; research funding from Gilead Sciences, Inc., AbbVie GK., FUJIREBIO Inc., Sysmex Corp., Janssen Pharmaceutical K.K. and GlaxoSmithKline PLC. Daisuke Nakamoto, Yi Piao, Hajime Mizutani, Kyung min Kwon, and Harriet Dickinson are current employees of Gilead Sciences with stock ownership. Yoshiyuki Saito is a board member of Datack Inc. with stock ownership.
: This study was conducted following the World Medical Association’s Declaration of Helsinki, respecting the ethical standards for research involving human participants. This study did not require patient consent or approval from an institutional review board and independent ethics committee because the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects do not apply to studies exclusively on de-identified data.